Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The RPL17-C18orf32 readthrough is a product of natural readthrough transcription between the human RPL17 gene, which encodes a component of the 60S ribosomal subunit, and the adjacent C18orf32 gene. The resulting transcripts encode proteins that incorporate most of the RPL17 sequence but terminate with a distinct, frameshifted C-terminal extension derived from C18orf32 exons. While RPL17 is essential for ribosomal assembly and protein translation, and its mutations are linked to disorders such as Diamond-Blackfan anemia, the physiological and pathological roles of the RPL17-C18orf32 chimeric product are largely uncharacterized and not currently targeted by therapeutics[3][4][5][2][1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RPL17-C18orf32 readthrough (RPL17-C18orf32).